Business
The current state of political affairs in the U.S. does not bode well for the direction of that turn. The country is at real risk of losing its long-held lead in biotech innovation.
FEATURED STORIES
The rare disease drugmaker is facing potential competitors for achondroplasia drug Voxzogo. Is a big M&A deal with two approved assets enough to maintain investor interest?
A rapturous response to data published last year for Pelage’s hair loss candidate overwhelmed the biotech. Now, the company is ready to show the world the science behind the breakthrough.
Pfizer, Eli Lilly, Novartis, Bristol Myers Squibb and AstraZeneca are all ramping up the use of AI, but drug discovery is not the primary success story—yet.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Alpine Immune Sciences has entered into a collaboration agreement with Merck to evaluate the efficacy and safety of Alpine’s checkpoint in combination with Merk’s anti-PD-1 therapy in cancer.
The new funding will be used to advance the company’s potential best-in-class epidermal growth factor receptor tyrosine kinase inhibitor furmonertinib, a lung cancer treatment that has been licensed from Allist Pharmaceuticals.
Christina Smolke said the financing will enable the company to use its synthetic biology platform to support essential medications that rely on plant-based materials.
The two companies will collaborate to market Verogen’s forensically validated NGS workflows alongside QIAGEN’s full range of forensic-grade chemistries and sample prep automation.
Craig Fraser, CEO of Windtree Therapeutics, became a U.S. Marine at age 17, learning to perform and lead under pressure in the field before eventually leading in the C-suite.
The cash infusion will support the growth of its manufacturing capabilities in the US and the UK and the demands for gene therapies, antibodies, and vaccines such as COVID-19.
Major players in the biotech industry are targeting Ohio for their new facilities, including Amgen, which recently dropped $365 million on a “digitally advanced” smart facility just 15 miles outside the state’s capital.
Three partnerships were signed today between biopharmaceutical and therapeutics companies in a bid to develop treatment for major diseases with high mortality rates.
The deal was originally inked in 2005, where U.S.-based Chiron Corp. made payments to Genentech, a Roche company.
Tofersen is the furthest along of four ASOs currently in clinical development for ALS and as such, there is quite a bit riding on the results of the VALOR trial which has an estimated completion date of August 31st, 2021.